Drug intelligence / Profile preview

cyclosporine + hydroxychloroquine + prednisolone

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of cyclosporine, hydroxychloroquine, and prednisolone. This combination leverages the different immunomodulatory mechanisms of each component to achieve potentially synergistic effects in treating autoimmune and inflammatory conditions. Cyclosporine inhibits T-cell activation through calcineurin inhibition, hydroxychloroquine affects antigen presentation and innate immune responses, while prednisolone provides anti-inflammatory and immunosuppressive effects through glucocorticoid activity.

Targets

GR (Glucocorticoid receptor)CN (Calcineurin)

Beyond the preview

Go deeper on cyclosporine + hydroxychloroquine + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine + hydroxychloroquine + prednisolone.

Explore the full profile